In clinical situation, 64Cu-PCTA-cetuximab immuno-PET imaging could be a useful surrogate imaging biomarker that quantitatively evaluate the EGFR expression level and select pertinent HNSCC patients for radioimmunotherapy in cetuximab-resistant HNSCC patients. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.